Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial
Journal of the European Academy of Dermatology and Venereology2020Vol. 35(4), pp. 938–947
Citations Over TimeTop 10% of 2020 papers
Christine Bodemer, Andrzej Kaszuba, Külli Kingo, Athanasios Tsianakas, Akimichi Morita, Enrique Rivas, P. Papanastasiou, Deborah Keefe, Manmath Patekar, Pascal Charef, L. Zhang, Susan Cafoncelli, C. Papavassilis
Abstract
Both doses of secukinumab demonstrated high and sustained efficacy up to Week 52 with a favourable safety profile in paediatric patients with severe chronic plaque psoriasis.
Related Papers
- → A Review of Secukinumab in Psoriasis Treatment(2020)22 cited
- → Secukinumab (AIN-457) for the treatment of Psoriasis(2015)13 cited
- → Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs(2021)4 cited
- → AB0639 TREATMENT EFFICACY WITH SECUKINUMAB IN A COHORT OF SPONDYLOARTHRITIS PATIENTS(2020)
- → 17731 Evolving resolution of clinical, cellular, and transcriptomic inflammatory markers during 1-year IL-17A inhibition by secukinumab(2020)